Related Experiment Video
Updated: Sep 9, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third
Caroline Korves1, Martin Kulldorff2, Abirami S Balajee1
1White River Junction Veterans Affairs Medical Center, White River Junction, VT, United States.
Background:
Waning vaccine effectiveness (VE) evaluations are affected by multiple biases, many of which could be implicitly adjusted by using self-controlled methods.
Methods:
We used a self-controlled risk interval (SCRI) design to evaluate waning COVID-19 monovalent third dose effectiveness against laboratory-confirmed SARS-CoV-2 medically-attended infections (cases) and hospitalizations with COVID-19 discharge diagnosis among Veterans Health Administration enrollees who received a third dose 15 December 2021-31 August 2022. We used weeks 3-8 post-third dose as reference interval, representing the period of peak VE. We classified cases/hospitalizations occurring after this window into separate weekly risk intervals until 34 weeks post-third dose, using logistic regression to compare outcome risks in each interval with reference interval, adding an offset term to adjust for time-varying viral circulation. For comparison, we conducted a test-negative design (TND) analysis with similar criteria.
Results:
For the SCRI analysis, among 609,612 qualifying veterans who received a third dose, we identified 15,224 SARS-CoV-2 eligible cases. Short-term third dose VE relative to primary series was 47 % (95 %CI 41, 50). Waning of protection was evident by week 12 (incidence rate ratio [IRR] 1.5, 95 %CI 1.3, 1.7). By week 20, the IRR (1.9; 95 %CI 1.7, 2.1) was similar to that immediately after the third dose. We identified 3714 hospitalizations with a COVID-19 discharge diagnosis. At weeks 15-16 post-third dose and thereafter, the IRR was consistently above the null. IRR reached 2.3 (95 %CI 2.0, 2.7) by weeks 33-34 post-third dose. Similarly, the TND analysis showed short-term VE of 53 % (95 %CI 51, 55) and waning by week 13 (odds ratio 1.2, 95 %CI 1.0, 1.3).
Conclusion:
Protection against medically-attended infection waned within four months, while protection against hospitalization lasted longer. This demonstrates value of self-controlled methods as tools to evaluate waning of VE with observational data.
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Desensitization and Tachyphylaxis

